Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.76 |
| ▸ | CHKA | P35790 | 2/20 | 0.76 |
| ▸ | NCF1 | P14598 | 2/20 | 0.76 |
| ▸ | CA2 | P00918 | 1/20 | 0.76 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.55 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.50 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1935642 | 0.98 | NCF1 (0.73) | PRMT6CHKANCF1CA2HRH3 | |
| SCHEMBL111330 | 0.95 | HRH3 (0.74) | PRMT6CHKANCF1CA2HRH3 | |
| SCHEMBL109000 | 0.93 | HRH3 (0.78) | PRMT6CHKANCF1CA2HRH3 | |
| SCHEMBL1934733 | 0.93 | HRH3 (0.78) | PRMT6CHKANCF1CA2HRH3 | |
| Hydrochloric Acid SCHEMBL1935722 | 0.91 | HRH3 (0.75) | PRMT6CHKANCF1CA2HRH3 | |
| SCHEMBL24564964 | 0.91 | PRMT6 (0.69) | PRMT6CHKANCF1CA2HRH3 | |
| SCHEMBL12614113 | 0.90 | HRH3 (0.77) | PRMT6CHKANCF1CA2HRH3 | |
| SCHEMBL110133 | 0.87 | CHKA (1.00) | PRMT6CHKANCF1CA2KDM4E | |
| Benzylamine SCHEMBL16584747 | 0.84 | PRMT6 (0.73) | PRMT6CHKANCF1CA2HRH3 | |
| SCHEMBL30364132 | 0.84 | PRMT6 (0.93) | PRMT6CHKANCF1CA2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | PRMT6 2672/4885CHKA 1361/4885NCF1 1517/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | PRMT6 2650/4885CHKA 1183/4885NCF1 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.